In keeping with our mission to provide comprehensive advertising analysis, MediaRadar puts together a report of the most important mergers and acquisitions news each week. Stay in the loop, whether you sell advertising space or focus on business development.
This week, Autodesk gained Pype, HEICO made a specialized purchase with Connect Tech and Johnson & Johnson broadened its leadership in immune-mediated pharmaceuticals by acquiring Momenta Pharmaceuticals.
Autodesk, known for its software services used for architecture, engineering, construction, manufacturing, media, education, and entertainment industries, acquired Pype Inc. Pype makes software that helps analyze and extract construction data for building projects.
The deal marks Autodesk’s first AI-related acquisition. Following the acquisition, Autodesk plans to integregrate Pype products with Autodesk’s Construction Cloud. The company aims to use Pype’s software to help customers digitize the construction workflow process.
The addition of AI and machine learning to Autodesk’s software will minimize tedious manual entry and other steps prone to human error.
Pype’s software is able to scan thousands of pages of documents containing all the requirements for a construction project, producing data-driven estimates for cost and scope of various projects.
Financial terms of the deal have not been made public.
Aerospace company HEICO acquired 89.99% of Connect Tech Inc, a company that designs and manufactures small-form-factor embedded computing solutions.
The deal is HEICO’s 6th highly specialized, niche acquisition in the current fiscal year, and fourth since the onset of the COVID-19 pandemic.
Connect Tech is the largest global embedded hardware partner for the tech company NVIDIA. CTI’s commercial products are designed to withstand harsh environments and are primarily used in rugged commercial and industrial industries.
The company employs a team of 65 personnel; HEICO stated it does not expect any staff turnover as a result of the acquisition, and CTI will continue to operate out of its design and manufacturing facility in Ontario.
The acquisition was financed in cash at closing, and potential additional cash consideration is to be paid if certain post-closing earnings levels are attained. Financial terms of the deal have not been made public.
Johnson & Johnson announced that it agreed to acquire drugmaker Momenta Pharmaceuticals Inc. for $6.5 billion, a 70% premium on Momenta’s closing price on August 18, 2020.
Momenta is a biotechnology company focused on discovering and developing novel therapies to treat immune-mediated diseases. By acquiring Momenta, J&J gains access to its experimental drug – nipocalimab, which is part of a newer class of autoimmune drugs known as FcRn antibodies.
According to Wall Street analysts, several companies including Alexion Pharmaceuticals are developing FcRn antibodies, but nipocalimab is one of the most clinically advanced, and it bodes well for J&J’s development of this molecule.
The analysts also added that this new class of drugs could generate sales of more than $20 billion in the U.S. by 2030. As a result, this acquisition paves the way for J&J to expand its efforts into autoimmune disease treatments and broadens its leadership in immune-mediated diseases.
Here are further developments from this past week: